Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biotechnol Adv. 2001 Oct;19(6):435-50.

Advances in pretargeting biotechnology.

Author information

  • 1Nuclear Medicine Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA. goodwinda83@hotmail.com

Abstract

A major focus of current drug research is to improve drug targeting to internal target sites such as to solid tumors or specific organs. The objective of drug targeting, especially for cancer chemotherapy and radioimmunotherapy, is to enhance the effectiveness of the drug by concentrating it at the target site and minimizing its effects in nontarget sites. Although tumor targeting has been obtained with large long-circulating radiolabeled antibody molecules, normal organ activity, especially in the blood kidneys, liver, and bone marrow is a significant problem. Over the last 20 years, studies to improve the therapeutic use of antibodies have included the use of antibody fragments, chase molecules, metabolizable linkers, antibody-directed enzyme prodrugs (ADEPT), local delivery, and pretargeting. Here, we will review the most interesting recent advances in pretargeting biotechnology.

PMID:
14538068
[PubMed]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk